Tempest Therapeutics Net Income Applicable To Common Shares Over Time
| TPST Stock | USD 1.84 -0.45 -19.65% |
Fundamental trend analysis helps separate temporary noise from persistent changes in Tempest Therapeutics. All values are presented as reference data.
Context for Tempest Therapeutics is enhanced by combining Tempest Therapeutics Performance with Tempest Therapeutics Correlation.Investors evaluate Tempest Therapeutics using market value and book value, each describing different facets of the business. All metrics are derived from available inputs and shown for reference.
Value and price for Tempest Therapeutics may converge over time but can differ substantially in any given period. All metrics are derived from available inputs and shown for reference.
Peer Comparison: Net Income Applicable To Common Shares
The net income that remains after preferred dividends have been deducted, available to common shareholders.Compare Tempest Therapeutics and related stocks such as OnKure Therapeutics, Kezar Life Sciences, and FibroGen Net Income Applicable To Common Shares Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KZR | -9 M | -9 M | -9 M | -9 M | -9 M | -9 M | -9 M | -8.5 M | -23.2 M | -35.1 M | -41.7 M | -54.6 M | -68.2 M | -68.2 M | -68.2 M | -61.4 M | -58.3 M |
| ALGS | -15.2 M | -15.2 M | -15.2 M | -15.2 M | -15.2 M | -15.2 M | -15.2 M | -15.2 M | -15.2 M | -52.3 M | -108.5 M | -128.3 M | -96 M | -96 M | -96 M | -86.4 M | -90.8 M |
| XLO | -17.3 M | -17.3 M | -17.3 M | -17.3 M | -17.3 M | -17.3 M | -17.3 M | -17.3 M | -17.3 M | -17.3 M | -55.2 M | -75.8 M | -88.2 M | -88.2 M | -88.2 M | -79.4 M | -83.4 M |
| PDSB | -32.4 M | -32.4 M | -32.4 M | -32.4 M | -32.4 M | -32.4 M | -4.5 M | -3.4 M | -3.8 M | -7 M | -14.8 M | -16.9 M | -40.9 M | -40.9 M | -40.9 M | -36.8 M | -34.9 M |
| ATNM | -10.8 M | -10.8 M | -10.8 M | -10.8 M | -24.7 M | -21 M | -24.3 M | -26.6 M | -23.7 M | -21.9 M | -22.2 M | -24.8 M | -33 M | -33 M | -33 M | -29.7 M | -31.2 M |
| BRNS | -20.7 M | -20.7 M | -20.7 M | -20.7 M | -20.7 M | -20.7 M | -20.7 M | -20.7 M | -20.7 M | -20.7 M | -17.7 M | -50.9 M | -50.9 M | -50.9 M | -50.9 M | -45.8 M | -48.1 M |
| INMB | -48.9 K | -48.9 K | -48.9 K | -48.9 K | -48.9 K | -48.9 K | -277.5 K | -831.5 K | -12.4 M | -7.7 M | -12.1 M | -30.3 M | -27.3 M | -27.3 M | -27.3 M | -24.6 M | -23.3 M |
My Equities
My Current Equities and Potential Positions
| Tempest Therapeutics | TPST |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 2000 Sierra Point |
| Exchange | NASDAQ Exchange |
USD 1.84
Additional Tools for Tempest Stock Analysis
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |